Avantor’s lower-than-expected guidance triggered a 10.35% one-month decline, underperforming broader markets amid sector volatility.
Avantor (AVTR) shares fell to $7.62 on May 15, 2026, after issuing guidance that disappointed investors. The stock posted a one-month return of -10.35% and a 52-week loss of 42.96%, reflecting broader sector challenges.
The company, with a $5.20 billion market capitalization, serves biotechnology and pharmaceutical sectors. Its underperformance contrasted with the S&P 500’s -4.33% quarterly decline, as rising private credit risks and geopolitical tensions pressured equities.
Longleaf Partners Fund noted AVTR’s struggles in its Q1 2026 investor letter, citing sector-wide volatility and macroeconomic headwinds as key factors.